Clermont-Ferrand University Hospital
Clermont-Ferrand, Auvergne, 63000, France
NCT Number: NCT04610931
Tobacco is an addiction with serious consequences: somatic, psychiatric... The number of requests for treatment for tobacco addiction is gradually increasing from year to year, but conventional treatments have limited effectiveness. New tools such as virtual reality could be used in this treatment. We propose to create a virtual reality program based on the analysis of high-risk relapse situations. The investigator will then evaluate the effect of this cybertherapy on patients' relapse time and their desire to smoke.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Not applicable
Clermont-Ferrand, Auvergne, 63000, France
Smoking is the leading cause of morbidity and mortality, making it one of the most serious public health problems in the world. The majority of smokers would like to stop smoking and the number of smokers seeking treatment has increased by 25% between 2017 and 2018 in France. Indeed, many effective interventions have been developed to stop smoking, but many patients continue to relapse after a quit attempt. Only 10% to 30% achieve long-term abstinence and the majority relapse.
The therapeutic approach to addiction is based on a bio-psycho-social model. It aims to limit the runaway of subcortical processes (the cause of craving) via a medicinal approach and to strengthen the cortical control mechanisms via a psychotherapeutic approach.
As far as psychotherapeutic approaches are concerned, they seek to obtain a modification of cognitions and emotions related to tobacco through, for example, a relearning of the management of the product mediated by evocation or exposure. This may involve, for example, the repeated presentation (or evocation) of a signal (e.g. a place of consumption...), previously linked to consumption but in the absence of a reinforcer (product consumption). Most addiction remediation therapies have been developed and practiced with "imagination" (the patient is asked to think of stimulating situations) but they are difficult to control (because the patient's imagination can be more or less large) and are rarely used with situations that induce consumption. In this context the use of a 3Dimension (3D) tool, which allows a controlled and progressive exposure without confrontation, seems an interesting perspective. Virtual reality is recognized as a "tool" in the fields of neuroscience and psychology. It allows a patient-controlled exposure to complex, dynamic and three-dimensional stimuli.
Thus, virtual reality has logically been proposed as a tool in exposure therapies and its benefit has been measured in substance dependencies (Hone-Blanchet et al 2014). Since 2000, several researchers have successfully used virtual reality applications in addictions, but there is little data on objective evaluations of the effectiveness of cybertherapy in the treatment of tobacco addiction, particularly in association with the two reference treatments for smoking cessation that are nicotine substitution associated with cognitive behavioural therapy. For tobacco, the results are heterogeneous and did not take into account the different factors for maintaining tobacco use (Lee et al 2004, Choi et al 2011, Park et al 2014). Virtual therapy appears to be more effective when combined with other relapse prevention techniques such as cognitive behavioural therapy (CBT).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups.
In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.
Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups. Subjects in the Virtual Reality group will receive 6 weekly individual CBT sessions followed by 6 virtual therapy sessions. Virtual therapy consists of exposing the patient to 3D situations considered to cause a high risk of smoking relapse and aiming to reduce signal reactivity by extinction. At each session, a neutral exposure will be given at the beginning to facilitate immersion and emergence of the session with a duration determined according to the sensitivity of each patient. Exposure is stopped when the craving approaches the baseline level.
Participants are smokers seeking treatment. Patients will be randomized into one of the 2 intervention groups. In all cases, patients will receive nicotine replacement therapy. The second physician in charge of the usual tobacco monitoring will adjust the dosage.
Subjects in the usual treatment group will receive 6 weekly individual cognitive behavior therapy sessions lead by a psychologist. The content of CBT is similar in both groups.
Time frame: Day 43
Comparison of proportion of patients who quit smoking after 6 weeks after intervention in the 2 arms (declarative status verified by measurement of carbon monoxide level in the expired air) and until one year.
Time frame: Day 136
Comparison of proportion of patients who quit smoking after 6 weeks after intervention in the 2 arms (declarative status verified by measurement of carbon monoxide level in the expired air) and until one year.
Time frame: Day 229
Comparison of proportion of patients who quit smoking after 6 weeks after intervention in the 2 arms (declarative status verified by measurement of carbon monoxide level in the expired air) and until one year.
Time frame: Day 408
Comparison of proportion of patients who quit smoking after 6 weeks after intervention in the 2 arms (declarative status verified by measurement of carbon monoxide level in the expired air) and until one year.
Time frame: Day 229, Day 408
Comparison between arms of mean/median number of cigarette smoke per day (declarative status and measurement of carbon monoxide level in the expired air)
Time frame: Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
evaluation of craving score with Tabacco Craving Questionnary sort Form questionnaire (7 to 84; 7 no craving and 84 highest craving) ; comparison between arms at different endpoints
Time frame: Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
It is evaluated with an analogical visual scale (1 to 10; 1 the lowest 10 the highest); comparison between arms at different endpoints
Time frame: Day 1, Day 43
It is evaluated with disease simulation questionnaire (French Speach Spatial en Quality -SSQ-vf- questionnaire)(/16)
Time frame: Day 43
Follow-up of all virtual reality sessions is assessed at 6 weeks post-inclusion
Time frame: Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
Relapse rate is the percentage of participants who are abstinent at the end of treatment and who relapse during the follow-up period; comparison between arms at different endpoints
Time frame: Day 1, Day 43, Day 74, Day 136, Day 229, Day 408
It is evaluated with the Hospital Anxiety and Depression - HAD scale (1 to 21; 1 no anxiety and depression , 21 highest symptoms); comparison between arms at different endpoints
University Hospital, Clermont-Ferrand
Other
Acronym: 3DSmoke
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03194958
Behavior, Behavior, Addictive
St Louis, Missouri, United States
View Trial DetailsNCT00218413
Behavior, Behavior, Addictive
Maastricht, Netherlands
View Trial DetailsNCT06483412
Addiction, Behavior
Palo Alto, California, United States
View Trial DetailsNCT06629467
Behavior, Health Behavior
Oviedo, Principality of Asturias, Spain
View Trial Details